Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery
Business Wire•09/10/2026•07:00 ET
0
Key Highlights
- ➤iDose TR plus cataract surgery cut mean diurnal IOP 11.1 mmHg at month three
- ➤Cataract surgery alone reduced mean diurnal IOP 7.4 mmHg at month three
- ➤iDose TR showed statistically significant superiority, with 3.6 mmHg incremental benefit
- ➤Phase 4 trial randomized 149 eyes, including 74 receiving iDose TR combination therapy
- ➤No treatment-related corneal endothelial cell loss, CME, or serious corneal events through three months
Expert Statements
Thomas Burns, Chairman and Chief Executive Officer of Glaukos
“We are pleased to announce these positive Phase 4 results, which add to the extensive body of clinical evidence supporting the efficacy, durability, and safety of iDose TR”
Thomas Burns, Chairman and Chief Executive Officer of Glaukos
“Importantly, these data further reinforce the versatility of iDose TR across various administration settings, demonstrating its ability to deliver clinically meaningful robust IOP reduction whether administered as a standalone procedure or in conjunction with cataract surgery.”
Thomas Burns, Chairman and Chief Executive Officer of Glaukos
“iDose TR continues to deliver strong clinical outcomes that provide meaningful benefits for patients, helping to accelerate a broader treatment paradigm shift toward earlier, interventional glaucoma care.”
Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose(®) TR in Combination with Cataract Surgery
Study Met Primary Efficacy Endpoint, Demonstrating Statistically Significant Superiority and Clinically Meaningful IOP Reduction vs. Cataract Surgery Alone
Get started
Create a free account to read the full story.